Longevity & AgingNew Drug Combo Adds 4.5% More Weight Loss on Top of Tirzepatide in Trial
OrsoBio has reported early clinical results showing that adding its oral drug TLC-6740 to tirzepatide — already one of the most effective weight-loss medications available — produced an additional 4.5% body weight reduction over 24 weeks compared to tirzepatide alone. The Phase 2a trial also found improvements in insulin sensitivity, liver health, and body composition, with no serious adverse events. The drug works by targeting mitochondria to increase how much energy the body burns. A related compound, TLC-1180, showed striking results in mice, including preserved muscle mass, better metabolic health across multiple organs, improved exercise capacity, and even reduced obesity-linked cognitive decline. TLC-1180 has now entered human safety trials.
